Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834079 | 0.92 | NHERF1 (0.44) | PARP14ALBKDM4ENHERF1LMNA | |
| SCHEMBL6833821 | 0.91 | NHERF1 (0.43) | PARP14ALBKDM4ENHERF1KCNQ2 | |
| SCHEMBL6834298 | 0.90 | MEN1 (0.44) | PARP14KDM4ELMNA | |
| SCHEMBL6834504 | 0.90 | LMNA (0.47) | PARP14ALBKDM4ENHERF1LMNA | |
| SCHEMBL6830460 | 0.89 | TRPM4 (0.42) | PARP14ALBKDM4EPRSS12NHERF1 | |
| SCHEMBL6834072 | 0.88 | ALDH1A1 (0.41) | PARP14ALBKDM4EMAPTLMNA | |
| SCHEMBL6835671 | 0.88 | LMNA (0.39) | PARP14ALBMAPTLMNA | |
| SCHEMBL6833766 | 0.88 | PARP14 (0.43) | PARP14KDM4ELMNA | |
| SCHEMBL6834134 | 0.88 | IDO1 (0.43) | PARP14ALBKDM4EMAPTNHERF1 | |
| SCHEMBL6833087 | 0.87 | MEN1 (0.44) | PARP14ALBKDM4EPRSS12NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | TRPV1 992/4885PARP14 2395/4885ALB 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.